Navigation Links
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
Date:11/6/2008

NEW ORLEANS and CARLSBAD, Calif., Nov. 6

/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Isis' cardiovascular program review of development and

late-stage research candidates, including presentations

from:

-- Dr. Erik Stroes reporting top line data from an ongoing

Phase 2 mipomersen liver imaging study

-- Dr. Evan Stein providing an update on an open-label

extension study of mipomersen in subjects with familial

hypercholesterolemia

When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.

PT/7:00 p.m. ET)

Where: http://www.isispharm.com

How: Live on the Internet. Simply log onto the website listed

above.

Contacts: Kristina Lemonidis

Associate Director, Corporate Development

Isis Pharmaceuticals, Inc.

(760) 603-2490

Amy Blackley, Ph.D.

Manager, Corporate Communications

Isis Pharmaceuticals, Inc.

(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. GNC Schedules Conference Call and Webcast to Report 3rd Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. STERIS Corporation Announces Webcast of Analyst Conference
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11
6. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
7. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
9. Sunrise to Host Conference Call and Webcast to Discuss the Companys Financial Results for the Third Quarter 2008
10. Webcast Alert: Air Methods Corporation Announces Third Quarter 2008 Financial Results
11. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Federal Laboratory Consortium for Technology Transfer ... houses a wealth of federal resources that businesses can leverage to further develop ... (T2). As a network of over 300 federal laboratories, the FLC’s mission is ...
(Date:2/8/2016)... ... ... Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of affection ... year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... of the lives they’ve led and the people they’ve touched. , That’s why ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... footwear and clothing, announced expansion into Canada to provide its range of unique ... a sales office in Quebec City that will provide bilingual customer service and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its ... cancer. , Gary D. Radine, who recently retired as president and CEO of Delta ... 2015 CEO of the Year , helped lead the effort to raise funds ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... variety of organizations. DocuSyst provides a cloud hosted environment for FileHold software ... include integration with various 3rd party applications using the FileHold web services API. ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  ivWatch, a medical devices company, ... STEM Award granted by Governor Terry McAuliffe,s office. ... on February 25th at an event to be held at ... STEM award honors professionals and business that have made significant ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology: